Azithromycin for Treatment of COVID-19 HomeReviewsTherapy (NNT) ReviewsDiagnosis (LR) ReviewsAboutThe NNT, ExplainedThe NNT Rating SystemtheNNT Editorial ProcessThe NNT Intervention QuizAbout theNNT TeamSubmit an articleAccountLoginSign upContactDONATEAzithromycin for Treatment of COVID-19Azithromycin for Treatment of COVID-19 does not reduce mortality or improve clinical outcomesBenefits in NNTNo inpatients or outpatients with COVID-19 were helped (azithromycin [Zithromax] vs. standard of care or placebo)Harms in NNTNo one was harmedView As: NNT %SourceEcheverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, et al. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021;19(2):147-163.Study Population: 9,049 patients hospitalized with COVID-19 (inpatient
Covid-19: New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil) with azithromycin (Zithromax or other brands) Prescrire IN ENGLISH - Spotlight ''New data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands)'', 16 April 2020 {1}##LOC[OK]## {1} ##LOC[OK]## ##LOC[Cancel]## {1}##LOC of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands) SpotlightEvery month, the subjects in Prescrire’s Spotlight. 100 most recent: 1|10|20|30|40|50|60|70|80|90Spotlight * 100 most recent * ArchivesNew data on the cardiac adverse effects of the combination of hydroxychloroquine (Plaquenil°) with azithromycin (Zithromax° or other brands
Covid-19 drug vignettes: Azithromycin Drug vignettes: Azithromycin - The Centre for Evidence-Based Medicine The Centre for Evidence-Based MedicineEvidence Service to support the COVID-19 responseNavigate this website * Home * COVID-19 Evidence * Open Evidence Reviews * Blog * Home * COVID-19 Evidence * Open Evidence Reviews * BlogDrug vignettes: AzithromycinMay 13, 2020Robin E Ferner*, Jeffrey K RNA-dependent protein synthesis.Some macrolides, including azithromycin, may reduce interleukin-6 (IL-6) production in vitro, and azithromycin accumulates in lung fluid. Since IL-6 contributes to the cytokine storm associated with influenza and other viral infections, azithromycin has been proposed as a potential modifier of severe viral infections.It was reported in a brief abstract from Wuhan
Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. March 23, 2020 Dr Darren Dahly, PhD - Principal Statistician, HRB Clinical Research Facility - Cork. HRB Trial is licensed under a Creative Commons Attribution 4.0 International License2. DOI:10.5281/zenodo.3724167 Study Summary Here we review Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, by Gautret et al. When we started our review, the paper was being circulated via Google Drive. Shortly after, it was accepted for publication
Azithromycin removal from water via adsorption on drinking water sludge-derived materials: Kinetics and isotherms studies. In this study, we utilized drinking water treatment sludge (WTS) to produce adsorbents through the drying and calcination process. These adsorbents were then evaluated for their ability to remove azithromycin (AZT) from aqueous solutions. The L-500 adsorbent, derived from
Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 - American College of Cardiology * Guidelines * JACC * ACC.23/WCC * Members * About * JoinCreate Free Account or Log in to MyACC Menu Home * Clinical Topics * Acute Coronary Syndromes * Anticoagulation Guide * Clinical Toolkits * Clinician Well-Being Portal * Diversity and Inclusion * Expert Consensus Decision Pathways * Infographics * Mobile and Web Apps * Quality Programs < Back to Listings Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19Mar 29, 2020 Cardiology MagazineShare via: * PrintFont Size A A A KEY POINTS
Hydroxychloroquine with or without azithromycin for COVID-19 Tools for Practice is proudly sponsored by the Alberta College of Family Physicians (ACFP). ACFP is a provincial, professional voluntary organization, representing more than 4,800 family physicians, family medicine residents, and medical students in Alberta. Established over sixty years ago, the ACFP strives for excellence in family best to stay in front and keep you up-to-date during these challenging times. Hydroxychloroquine with or without azithromycin for COVID-19 Clinical Question: Is hydroxychloroquine (with or without azithromycin) effective in treating COVID-19? Bottom Line: One nonrandomized study found that more hydroxychloroquine/azithromycin patients tested negative for virus at days 3
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? ACP Journals LOGIN TO YOUR ACCOUNTINDIVIDUAL LOGIN | REGISTER or INSTITUTIONAL LOGIN INSTITUTIONAL ADMIN LOGIN Create a new accountEmail Returning user Can't sign in? Forgot your password?Enter your email address below and we will send you
Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso: The CHAT Randomized Clinical Trial. Repeated mass distribution of azithromycin has been shown to reduce childhood mortality by 14% in sub-Saharan Africa. However, the estimated effect varied by location, suggesting that the intervention may not be effective in different geographical areas, time periods, or conditions . To evaluate the efficacy of twice-yearly azithromycin to reduce mortality in children in the presence of seasonal malaria chemoprevention. This cluster randomized placebo-controlled trial evaluating the efficacy of single-dose azithromycin for prevention of all-cause childhood mortality included 341 communities in the Nouna district in rural northwestern Burkina Faso. Participants were children aged 1 to 59
Single-dose azithromycin for infant growth in Burkina Faso: Prespecified secondary anthropometric outcomes from a randomized controlled trial Antibiotic use during early infancy has been linked to childhood obesity in high-income countries. We evaluated whether a single oral dose of azithromycin administered during infant-well visits led to changes in infant growth outcomes at 6 months of age in a setting with a high prevalence of undernutrition in rural Burkina Faso. Infants were enrolled from September 25, 2019, until October 22, 2022, in a randomized controlled trial designed to evaluate the efficacy of a single oral dose of azithromycin (20 mg/kg) compared to placebo when administered during well-child visits for prevention of infant mortality. The trial found no evidence of a difference
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial Systematic reviews have reported conflicting evidence on whether macrolide antibiotics reduce rates of chronic lung disease of prematurity (CLD) in at-risk preterm infants born at less than 30 weeks' gestation, including in those colonised with pulmonary Ureaplasma spp. Since an adequately powered trial has been lacking, we aimed to assess if the macrolide azithromycin improved survival without the development of physiologically defined moderate or severe CLD in preterm infants. AZTEC was a multicentre, double-blind, randomised, placebo-controlled trial conducted in 28 tertiary neonatal intensive care units in the UK. Infants were eligible
Impact of mutations in the mtrR, rpdlVD and rrl genes on azithromycin resistance in Neisseria gonorrhoeae. Bacterial sexually transmitted infections (STIs) pose a major public health problem. The emergence of antibiotic-resistant strains of Neisseria gonorrhoeae represents a serious threat to successful treatment and epidemiological control. The first extensively drug-resistant (XDR) strains (ceftriaxone-resistant and high-level azithromycin-resistant [HLR AZY]) have been reported. To identify molecular mechanisms implicated in azithromycin resistance in strains isolated from patients over a three-year period in a university hospital in Switzerland. From January 2020 to December 2022, 34 isolates (one per patient) were recovered from samples analyzed at the University Hospital of Lausanne. Eight
A phase II, multicenter, nonblinded, randomized controlled trial for evaluating protective effects of ABPC/SBT plus, azithromycin versus erythromycin, in pregnant women with pPROM occurring at <28 weeks of gestation on the development of BPD in neonates: This is a protocol for PPROM-AZM Study, phase II, nonblinded, randomized controlled trial. Bronchopulmonary dysplasia (BPD) at a postmenstrual on the prevention of moderate/severe BPD36 using the standard treatment has not been confirmed. Recently, it is reported that ampicillin/sulbactam (ABPC/SBT) plus azithromycin (AZM) was effective for the prevention of moderate/severe BPD36 in pPROM patients with amniotic infection of Ureaplasma species. Therefore, our aim is to evaluate the occurrence rate of the composite outcome of "incidence rate of either
Azithromycin during Routine Well-Infant Visits to Prevent Death. Mass distribution of azithromycin to children 1 to 59 months of age has been shown to reduce childhood all-cause mortality in some sub-Saharan African regions, with the largest reduction seen among infants younger than 12 months of age. Whether the administration of azithromycin at routine health care visits for infants would be effective in preventing death is unclear. We conducted a randomized, placebo-controlled trial of a single dose of azithromycin (20 mg per kilogram of body weight) as compared with placebo, administered during infancy (5 to 12 weeks of age). The primary end point was death before 6 months of age. Infants were recruited at routine vaccination or other well-child visits in clinics and through community
Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial Asthma remission is a potential treatment goal. Does adding azithromycin to standard therapy in patients with persistent uncontrolled asthma induce remission compared to placebo? This secondary analysis used data from the AMAZES clinical trial - a double-blind placebo-controlled trial that evaluated the safety and efficacy of azithromycin on asthma exacerbations. The primary remission definition (referred to as clinical remission) was zero exacerbations and zero oral corticosteroids (OCS) during the previous six months evaluated at 12 months and Asthma Control Questionnaire (ACQ-5) ≤1 at 12 months. Secondary remission
Divergent effects of azithromycin on purple corn (Zea mays L.) cultivation: Impact on biomass and antioxidant compounds. The present study assessed the impact of using irrigation water contaminated with Azithromycin (AZM) residues on the biomass and antioxidant compounds of purple corn; for this purpose, the plants were cultivated under ambient conditions, and the substrate used consisted of soil
Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From * LATEST * ISSUES * IN THE CLINIC * JOURNAL CLUB * MULTIMEDIA * CME / MOC * Authors / Submit * subscribeLetters21 July 2020Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of PhysiciansFREE * Amir Qaseem, MD, PhD, MHA, * Jennifer Yost, RN, PhD
Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial. Twice-yearly mass distribution of azithromycin to children is a promising intervention to reduce childhood mortality in sub-Saharan Africa. The World Health Organization recommended restricting distribution to infants 1 to 11 months of age to mitigate antimicrobial resistance, although this more limited treatment had not yet been tested. We randomly assigned rural communities in Niger to four twice-yearly distributions of azithromycin for children 1 to 59 months of age (child azithromycin group), four twice-yearly distributions of azithromycin for infants 1 to 11 months of age and placebo for children 12 to 59 months of age (infant azithromycin group), or placebo for children 1 to 59 months of age. Census workers